Compare WINA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | HRMY |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.0B |
| IPO Year | 1993 | 2020 |
| Metric | WINA | HRMY |
|---|---|---|
| Price | $426.96 | $39.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $51.33 |
| AVG Volume (30 Days) | 84.2K | ★ 780.1K |
| Earning Date | 10-15-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | 2.56 | ★ 50.44 |
| EPS | ★ 11.21 | 3.17 |
| Revenue | $84,517,400.00 | ★ $825,944,000.00 |
| Revenue This Year | $7.05 | $20.68 |
| Revenue Next Year | $3.60 | $15.93 |
| P/E Ratio | $38.01 | ★ $12.57 |
| Revenue Growth | 3.35 | ★ 21.13 |
| 52 Week Low | $295.79 | $25.52 |
| 52 Week High | $527.37 | $40.93 |
| Indicator | WINA | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 84.53 |
| Support Level | $405.86 | $32.77 |
| Resistance Level | $432.21 | $36.20 |
| Average True Range (ATR) | 15.68 | 1.21 |
| MACD | 2.91 | 0.36 |
| Stochastic Oscillator | 68.18 | 96.26 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.